0001415889-23-015458.txt : 20231122 0001415889-23-015458.hdr.sgml : 20231122 20231122190020 ACCESSION NUMBER: 0001415889-23-015458 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231120 FILED AS OF DATE: 20231122 DATE AS OF CHANGE: 20231122 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Myles David C. CENTRAL INDEX KEY: 0001831216 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39712 FILM NUMBER: 231434748 MAIL ADDRESS: STREET 1: C/O OLEMA PHARMACEUTICALS, INC. STREET 2: 512 2ND STREET, 4TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94107 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Olema Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001750284 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 300409740 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 780 BRANNAN STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94103 BUSINESS PHONE: (415) 651-3316 MAIL ADDRESS: STREET 1: 780 BRANNAN STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94103 4 1 form4-11222023_071109.xml X0508 4 2023-11-20 0001750284 Olema Pharmaceuticals, Inc. OLMA 0001831216 Myles David C. C/O OLEMA PHARMACEUTICALS, INC. 780 BRANNAN ST SAN FRANCISCO CA 94103 false true false false CH. DISCOV. & NON-CLIN DEV OFF 0 Common Stock 2023-11-20 4 A 0 26250 0 A 587728 D Common Stock 2023-11-21 4 S 0 6776 14.87 D 580952 D Common Stock 2023-11-21 4 S 0 200 15.32 D 580752 D Common Stock 2023-11-22 4 S 0 6653 13.89 D 574099 D Common Stock 12831 I See Footnote Common Stock 154846 I See Footnote On November 11, 2022, the Reporting Person was granted certain performance restricted stock units ("PRSUs") for 75,000 shares, which are subject to vesting upon certification by the Compensation Committee of the Company's achieving two different performance milestones. The Compensation Committee certified on November 20, 2023 that 35% of the award vested based upon the certification by the Compensation Committee as to certain performance criteria. Includes 208 shares acquired under the issuer's Employee Stock Purchase Plan on November 15, 2023. The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. The weighted average sale price for the transaction reported was $14.87, and the range of prices was between $14.26 and $15.25. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $15.32, and the range of prices was between $15.28 and $15.35. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $13.89, and the range of prices was between $13.62 and $14.15. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. The shares are held by The Myles Family Revocable Inter Vivos Trust, of which the Reporting Person is trustee. The shares are held by Myles Properties Inc., of which the Reporting Person is President. /s/ Shane Kovacs, Attorney-in-Fact 2023-11-22